| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oncolytic Virotherapy | 62 | 2024 | 515 | 10.760 |
Why?
|
| Glioblastoma | 120 | 2024 | 3482 | 10.490 |
Why?
|
| Brain Neoplasms | 192 | 2024 | 9025 | 9.560 |
Why?
|
| Oncolytic Viruses | 47 | 2024 | 344 | 9.220 |
Why?
|
| Glioma | 93 | 2024 | 3452 | 6.600 |
Why?
|
| Herpesvirus 1, Human | 60 | 2024 | 739 | 5.750 |
Why?
|
| Genetic Vectors | 84 | 2022 | 3388 | 3.930 |
Why?
|
| Simplexvirus | 40 | 2022 | 801 | 3.810 |
Why?
|
| Neurosurgical Procedures | 21 | 2022 | 2067 | 2.860 |
Why?
|
| Meningioma | 19 | 2022 | 1216 | 2.630 |
Why?
|
| Virus Replication | 46 | 2018 | 2426 | 2.060 |
Why?
|
| Meningeal Neoplasms | 18 | 2022 | 1246 | 1.990 |
Why?
|
| Immunotherapy | 28 | 2024 | 4642 | 1.950 |
Why?
|
| Adenoviridae | 18 | 2016 | 1084 | 1.800 |
Why?
|
| Central Nervous System Neoplasms | 12 | 2014 | 915 | 1.710 |
Why?
|
| Cyclophosphamide | 22 | 2009 | 2219 | 1.590 |
Why?
|
| Cancer Vaccines | 9 | 2018 | 1038 | 1.520 |
Why?
|
| Gene Transfer Techniques | 26 | 2019 | 1201 | 1.230 |
Why?
|
| Neurosurgery | 9 | 2022 | 679 | 1.190 |
Why?
|
| Neoplasms | 32 | 2023 | 22140 | 1.180 |
Why?
|
| Tumor Microenvironment | 23 | 2024 | 3873 | 1.170 |
Why?
|
| Viruses | 9 | 2016 | 372 | 1.170 |
Why?
|
| MicroRNAs | 23 | 2020 | 3758 | 1.130 |
Why?
|
| Radiosurgery | 7 | 2014 | 1339 | 1.130 |
Why?
|
| Neoplastic Stem Cells | 18 | 2020 | 1348 | 1.120 |
Why?
|
| Transgenes | 17 | 2009 | 1008 | 1.080 |
Why?
|
| Thymidine Kinase | 15 | 2016 | 286 | 1.010 |
Why?
|
| Craniotomy | 9 | 2023 | 741 | 1.000 |
Why?
|
| Antineoplastic Agents, Alkylating | 13 | 2020 | 617 | 0.990 |
Why?
|
| Herpes Simplex | 11 | 2021 | 465 | 0.970 |
Why?
|
| Mice, Nude | 48 | 2020 | 3605 | 0.950 |
Why?
|
| Humans | 357 | 2024 | 761208 | 0.950 |
Why?
|
| Neoplasm Recurrence, Local | 19 | 2022 | 9278 | 0.940 |
Why?
|
| Tumor Cells, Cultured | 48 | 2024 | 6124 | 0.850 |
Why?
|
| Animals | 198 | 2024 | 168079 | 0.840 |
Why?
|
| Cell Line, Tumor | 57 | 2022 | 16952 | 0.840 |
Why?
|
| Cytochrome P-450 CYP2B1 | 7 | 2005 | 21 | 0.840 |
Why?
|
| Exosomes | 6 | 2020 | 424 | 0.840 |
Why?
|
| Monitoring, Intraoperative | 4 | 2014 | 944 | 0.830 |
Why?
|
| Gliosarcoma | 17 | 2001 | 114 | 0.820 |
Why?
|
| Gene Expression Regulation, Neoplastic | 24 | 2023 | 8530 | 0.800 |
Why?
|
| Killer Cells, Natural | 8 | 2022 | 2194 | 0.790 |
Why?
|
| Prodrugs | 12 | 2020 | 262 | 0.760 |
Why?
|
| Astrocytoma | 7 | 2015 | 774 | 0.750 |
Why?
|
| Interferon-gamma | 9 | 2023 | 3155 | 0.740 |
Why?
|
| Mice | 120 | 2024 | 81326 | 0.730 |
Why?
|
| Histone Deacetylases | 3 | 2015 | 716 | 0.730 |
Why?
|
| Clinical Trials as Topic | 26 | 2024 | 8003 | 0.720 |
Why?
|
| Interleukin-12 | 2 | 2022 | 578 | 0.720 |
Why?
|
| Antineoplastic Agents | 26 | 2018 | 13632 | 0.710 |
Why?
|
| Neoplasms, Experimental | 7 | 2019 | 1225 | 0.710 |
Why?
|
| Aminolevulinic Acid | 2 | 2011 | 145 | 0.700 |
Why?
|
| Supratentorial Neoplasms | 2 | 2012 | 159 | 0.690 |
Why?
|
| Peripheral Nervous System Neoplasms | 4 | 2009 | 133 | 0.680 |
Why?
|
| Xenograft Model Antitumor Assays | 24 | 2024 | 3592 | 0.680 |
Why?
|
| Neovascularization, Pathologic | 12 | 2019 | 2636 | 0.680 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2015 | 774 | 0.680 |
Why?
|
| Chromosomes, Artificial, Bacterial | 8 | 2014 | 123 | 0.680 |
Why?
|
| Gene Expression | 24 | 2018 | 7571 | 0.660 |
Why?
|
| Blood-Brain Barrier | 10 | 2022 | 1027 | 0.660 |
Why?
|
| Cytomegalovirus Infections | 5 | 2021 | 828 | 0.660 |
Why?
|
| Ganciclovir | 12 | 2004 | 253 | 0.650 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2019 | 31 | 0.640 |
Why?
|
| Spheroids, Cellular | 8 | 2017 | 329 | 0.620 |
Why?
|
| Skull Neoplasms | 3 | 2015 | 173 | 0.610 |
Why?
|
| Poliovirus | 1 | 2018 | 106 | 0.610 |
Why?
|
| Combined Modality Therapy | 24 | 2018 | 8519 | 0.610 |
Why?
|
| Tumor Escape | 2 | 2021 | 371 | 0.600 |
Why?
|
| Protein Phosphatase 1 | 1 | 2018 | 134 | 0.580 |
Why?
|
| Molecular Targeted Therapy | 4 | 2019 | 2813 | 0.570 |
Why?
|
| Photosensitizing Agents | 2 | 2011 | 625 | 0.550 |
Why?
|
| T-Lymphocytes | 7 | 2024 | 10203 | 0.550 |
Why?
|
| Wakefulness | 3 | 2015 | 1264 | 0.540 |
Why?
|
| Antigens, Neoplasm | 7 | 2021 | 1985 | 0.540 |
Why?
|
| Central Nervous System Cysts | 1 | 2016 | 56 | 0.530 |
Why?
|
| Valproic Acid | 4 | 2015 | 443 | 0.530 |
Why?
|
| Comovirus | 1 | 2015 | 5 | 0.530 |
Why?
|
| Neoplasm, Residual | 2 | 2013 | 1008 | 0.520 |
Why?
|
| Dermoid Cyst | 1 | 2016 | 92 | 0.520 |
Why?
|
| Viral Proteins | 10 | 2017 | 1798 | 0.510 |
Why?
|
| Defective Viruses | 3 | 2013 | 89 | 0.500 |
Why?
|
| Postoperative Complications | 8 | 2018 | 15637 | 0.500 |
Why?
|
| Lymphoma, B-Cell | 3 | 2013 | 938 | 0.500 |
Why?
|
| Helper Viruses | 4 | 2003 | 40 | 0.490 |
Why?
|
| Magnetic Resonance Imaging | 37 | 2021 | 36415 | 0.490 |
Why?
|
| Brachial Plexus Neuropathies | 2 | 2009 | 122 | 0.480 |
Why?
|
| Ventriculoperitoneal Shunt | 2 | 2016 | 187 | 0.470 |
Why?
|
| Immune Evasion | 1 | 2018 | 364 | 0.470 |
Why?
|
| Transfection | 15 | 2010 | 5748 | 0.450 |
Why?
|
| Peptides | 5 | 2020 | 4353 | 0.450 |
Why?
|
| Craniopharyngioma | 1 | 2016 | 276 | 0.450 |
Why?
|
| Dura Mater | 3 | 2012 | 290 | 0.450 |
Why?
|
| STAT3 Transcription Factor | 4 | 2020 | 872 | 0.440 |
Why?
|
| Neoplasm Invasiveness | 14 | 2017 | 3590 | 0.440 |
Why?
|
| Rats | 52 | 2012 | 23704 | 0.440 |
Why?
|
| Interferon-beta | 3 | 2015 | 345 | 0.430 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 3 | 1 | 2012 | 14 | 0.430 |
Why?
|
| Ubiquitins | 1 | 2014 | 366 | 0.430 |
Why?
|
| Sarcoma | 3 | 2014 | 1800 | 0.420 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 1 | 1 | 2012 | 29 | 0.420 |
Why?
|
| Genetic Engineering | 12 | 2014 | 930 | 0.420 |
Why?
|
| Streptavidin | 1 | 2013 | 81 | 0.420 |
Why?
|
| Chondrosarcoma | 2 | 2014 | 295 | 0.420 |
Why?
|
| Immunotherapy, Active | 1 | 2012 | 58 | 0.410 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 479 | 0.410 |
Why?
|
| Convection | 1 | 2012 | 30 | 0.410 |
Why?
|
| Anilides | 1 | 2015 | 411 | 0.410 |
Why?
|
| Female | 102 | 2024 | 392544 | 0.410 |
Why?
|
| Rats, Inbred F344 | 18 | 2011 | 826 | 0.410 |
Why?
|
| Cytomegalovirus | 5 | 2020 | 750 | 0.410 |
Why?
|
| Bacteriophage M13 | 1 | 2012 | 39 | 0.410 |
Why?
|
| Recombinant Fusion Proteins | 7 | 2017 | 3726 | 0.410 |
Why?
|
| Male | 95 | 2024 | 360693 | 0.410 |
Why?
|
| Glycoproteins | 2 | 2010 | 2203 | 0.410 |
Why?
|
| Immediate-Early Proteins | 4 | 2014 | 444 | 0.400 |
Why?
|
| Chordoma | 2 | 2014 | 347 | 0.400 |
Why?
|
| Skull Base Neoplasms | 2 | 2020 | 270 | 0.400 |
Why?
|
| Scalp | 1 | 2015 | 389 | 0.400 |
Why?
|
| Hemangioblastoma | 1 | 2012 | 62 | 0.400 |
Why?
|
| Megestrol Acetate | 1 | 2011 | 18 | 0.400 |
Why?
|
| Antigens, CD20 | 1 | 2013 | 199 | 0.400 |
Why?
|
| Ferric Compounds | 2 | 2013 | 378 | 0.390 |
Why?
|
| Cell Movement | 14 | 2017 | 5195 | 0.390 |
Why?
|
| Azacitidine | 1 | 2013 | 336 | 0.390 |
Why?
|
| Gene Amplification | 2 | 2017 | 1084 | 0.380 |
Why?
|
| Acyclovir | 4 | 2016 | 267 | 0.380 |
Why?
|
| Microglia | 4 | 2022 | 1358 | 0.380 |
Why?
|
| Melanoma | 6 | 2023 | 5694 | 0.380 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2022 | 11733 | 0.380 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2012 | 151 | 0.380 |
Why?
|
| Molecular Biology | 2 | 2014 | 573 | 0.370 |
Why?
|
| Acetamides | 1 | 2013 | 257 | 0.370 |
Why?
|
| Vero Cells | 17 | 2013 | 482 | 0.370 |
Why?
|
| Complement System Proteins | 4 | 2003 | 737 | 0.370 |
Why?
|
| STAT5 Transcription Factor | 1 | 2012 | 266 | 0.370 |
Why?
|
| Urinary Catheterization | 1 | 2012 | 193 | 0.370 |
Why?
|
| Antigens, CD | 3 | 2010 | 4009 | 0.370 |
Why?
|
| Lac Operon | 7 | 2002 | 237 | 0.360 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2011 | 63 | 0.360 |
Why?
|
| Brain Infarction | 1 | 2013 | 289 | 0.360 |
Why?
|
| Dacarbazine | 5 | 2017 | 559 | 0.360 |
Why?
|
| Cytochrome P-450 Enzyme System | 5 | 2004 | 413 | 0.360 |
Why?
|
| Protoporphyrins | 1 | 2011 | 168 | 0.360 |
Why?
|
| Genes, p16 | 3 | 2008 | 160 | 0.360 |
Why?
|
| Neoplasm Proteins | 6 | 2019 | 3594 | 0.360 |
Why?
|
| Seizures | 3 | 2024 | 2965 | 0.360 |
Why?
|
| Paraganglioma | 1 | 2012 | 143 | 0.360 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2012 | 258 | 0.350 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2015 | 1784 | 0.340 |
Why?
|
| Dexamethasone | 4 | 2022 | 1945 | 0.340 |
Why?
|
| Biomedical Research | 4 | 2021 | 3434 | 0.330 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2009 | 48 | 0.330 |
Why?
|
| Rhabdomyosarcoma | 1 | 2012 | 358 | 0.330 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2013 | 366 | 0.330 |
Why?
|
| Retroviridae | 9 | 2003 | 850 | 0.330 |
Why?
|
| Catheters, Indwelling | 1 | 2012 | 426 | 0.330 |
Why?
|
| Models, Biological | 11 | 2017 | 9457 | 0.330 |
Why?
|
| Complement Inactivator Proteins | 3 | 2004 | 74 | 0.330 |
Why?
|
| T-Box Domain Proteins | 1 | 2012 | 469 | 0.330 |
Why?
|
| Promoter Regions, Genetic | 10 | 2018 | 5773 | 0.320 |
Why?
|
| Neoplasm Transplantation | 18 | 2020 | 2010 | 0.320 |
Why?
|
| Disease Models, Animal | 26 | 2021 | 18220 | 0.320 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 12 | 2020 | 4567 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 5 | 2024 | 9187 | 0.320 |
Why?
|
| Diabetic Neuropathies | 1 | 2012 | 406 | 0.320 |
Why?
|
| Macrocyclic Compounds | 2 | 2020 | 68 | 0.320 |
Why?
|
| Efficiency, Organizational | 1 | 2013 | 695 | 0.320 |
Why?
|
| Spinal Nerves | 2 | 2007 | 90 | 0.320 |
Why?
|
| Gadolinium DTPA | 1 | 2012 | 823 | 0.320 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2013 | 549 | 0.320 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2011 | 371 | 0.320 |
Why?
|
| Microscopy, Confocal | 3 | 2011 | 1967 | 0.310 |
Why?
|
| Frontal Lobe | 4 | 2012 | 1416 | 0.310 |
Why?
|
| Electromagnetic Fields | 1 | 2010 | 289 | 0.310 |
Why?
|
| Cerebellar Neoplasms | 2 | 2013 | 586 | 0.310 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2010 | 321 | 0.310 |
Why?
|
| Cell Survival | 11 | 2018 | 5778 | 0.300 |
Why?
|
| Pituitary Neoplasms | 1 | 2016 | 1322 | 0.300 |
Why?
|
| Visual Pathways | 1 | 2012 | 550 | 0.300 |
Why?
|
| Nanoparticles | 2 | 2019 | 1959 | 0.300 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 3 | 2001 | 69 | 0.300 |
Why?
|
| Fibroblasts | 5 | 2015 | 4137 | 0.300 |
Why?
|
| Anticonvulsants | 3 | 2024 | 1910 | 0.290 |
Why?
|
| Valine | 3 | 2016 | 408 | 0.290 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2011 | 592 | 0.290 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2024 | 2549 | 0.290 |
Why?
|
| Causalgia | 1 | 2007 | 5 | 0.290 |
Why?
|
| Immunity, Innate | 5 | 2015 | 3044 | 0.290 |
Why?
|
| SEER Program | 1 | 2012 | 1453 | 0.280 |
Why?
|
| Herpesvirus 4, Human | 4 | 2012 | 1076 | 0.280 |
Why?
|
| Xanthines | 2 | 1997 | 120 | 0.280 |
Why?
|
| Pituitary Diseases | 1 | 2008 | 135 | 0.280 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2009 | 646 | 0.270 |
Why?
|
| Reoviridae | 2 | 2014 | 162 | 0.270 |
Why?
|
| Rats, Nude | 8 | 2012 | 106 | 0.270 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2015 | 2915 | 0.270 |
Why?
|
| Brain | 21 | 2024 | 27092 | 0.270 |
Why?
|
| Autophagy | 1 | 2014 | 1327 | 0.270 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2024 | 858 | 0.270 |
Why?
|
| Nervous System Diseases | 3 | 2012 | 1663 | 0.270 |
Why?
|
| Cytokines | 4 | 2014 | 7386 | 0.260 |
Why?
|
| DNA Primers | 4 | 2012 | 2814 | 0.260 |
Why?
|
| Cell Division | 13 | 2006 | 4451 | 0.260 |
Why?
|
| Stereotaxic Techniques | 7 | 2012 | 555 | 0.260 |
Why?
|
| Neurosciences | 1 | 2011 | 369 | 0.260 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2015 | 597 | 0.260 |
Why?
|
| Laser Therapy | 1 | 2013 | 1094 | 0.260 |
Why?
|
| Neoplasms, Second Primary | 1 | 2014 | 1052 | 0.260 |
Why?
|
| Oncogenes | 1 | 2011 | 1220 | 0.260 |
Why?
|
| Thalamus | 1 | 2012 | 1046 | 0.260 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2021 | 3770 | 0.250 |
Why?
|
| Cell Cycle | 6 | 2018 | 2925 | 0.250 |
Why?
|
| Conscious Sedation | 1 | 2010 | 533 | 0.250 |
Why?
|
| Carboxylesterase | 1 | 2005 | 31 | 0.250 |
Why?
|
| Urinary Tract Infections | 1 | 2012 | 801 | 0.250 |
Why?
|
| Visual Fields | 1 | 2012 | 1059 | 0.250 |
Why?
|
| Brain Ischemia | 2 | 2013 | 3032 | 0.250 |
Why?
|
| RNA, Neoplasm | 3 | 2017 | 748 | 0.250 |
Why?
|
| Signal Transduction | 20 | 2023 | 23416 | 0.240 |
Why?
|
| Spinal Cord Diseases | 2 | 2009 | 291 | 0.240 |
Why?
|
| Luminescent Measurements | 1 | 2006 | 340 | 0.240 |
Why?
|
| DNA, Viral | 8 | 2012 | 2195 | 0.240 |
Why?
|
| Fellowships and Scholarships | 1 | 2013 | 1115 | 0.240 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 416 | 0.240 |
Why?
|
| Neuronavigation | 2 | 2019 | 166 | 0.240 |
Why?
|
| Interleukin-4 | 4 | 2006 | 1154 | 0.240 |
Why?
|
| Antibodies | 1 | 2013 | 2415 | 0.240 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2020 | 1783 | 0.240 |
Why?
|
| Survival Analysis | 8 | 2023 | 10088 | 0.240 |
Why?
|
| Polyesters | 2 | 2009 | 371 | 0.230 |
Why?
|
| Immunohistochemistry | 17 | 2024 | 11067 | 0.230 |
Why?
|
| Cell Line | 16 | 2020 | 15545 | 0.230 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 2897 | 0.230 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2011 | 2047 | 0.230 |
Why?
|
| Immunity | 2 | 2022 | 996 | 0.230 |
Why?
|
| Radiotherapy | 2 | 2008 | 1499 | 0.230 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 4574 | 0.230 |
Why?
|
| RNA, Messenger | 8 | 2015 | 12747 | 0.230 |
Why?
|
| Patient Selection | 2 | 2014 | 4246 | 0.230 |
Why?
|
| Immunotoxins | 1 | 2004 | 175 | 0.230 |
Why?
|
| Radiation Injuries | 1 | 2011 | 1191 | 0.230 |
Why?
|
| Stem Cells | 4 | 2010 | 3517 | 0.220 |
Why?
|
| Dendritic Cells | 2 | 2012 | 2726 | 0.220 |
Why?
|
| Prognosis | 14 | 2020 | 29687 | 0.220 |
Why?
|
| STAT1 Transcription Factor | 2 | 2020 | 340 | 0.220 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2017 | 1351 | 0.220 |
Why?
|
| Treatment Outcome | 21 | 2024 | 64681 | 0.220 |
Why?
|
| Transduction, Genetic | 7 | 2022 | 900 | 0.220 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2011 | 1520 | 0.210 |
Why?
|
| Snake Venoms | 2 | 2013 | 38 | 0.210 |
Why?
|
| DNA, Complementary | 4 | 2014 | 1989 | 0.210 |
Why?
|
| Virus Physiological Phenomena | 1 | 2002 | 15 | 0.210 |
Why?
|
| Mutation | 19 | 2022 | 30002 | 0.210 |
Why?
|
| Anesthesia, General | 1 | 2010 | 1174 | 0.210 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2024 | 267 | 0.210 |
Why?
|
| Liver Neoplasms | 6 | 2013 | 4309 | 0.210 |
Why?
|
| Cell Proliferation | 15 | 2020 | 10422 | 0.210 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2013 | 2401 | 0.210 |
Why?
|
| Flucytosine | 2 | 2003 | 33 | 0.210 |
Why?
|
| Contrast Media | 5 | 2021 | 5311 | 0.210 |
Why?
|
| Uterine Neoplasms | 1 | 2011 | 1420 | 0.210 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2024 | 1468 | 0.210 |
Why?
|
| Antigens, Viral | 2 | 2020 | 989 | 0.200 |
Why?
|
| Cross Infection | 1 | 2012 | 1422 | 0.200 |
Why?
|
| Ribonucleotide Reductases | 6 | 2002 | 75 | 0.200 |
Why?
|
| Transglutaminases | 6 | 1991 | 196 | 0.200 |
Why?
|
| Mice, Inbred NOD | 3 | 2020 | 1822 | 0.200 |
Why?
|
| Electrodes, Implanted | 1 | 2007 | 839 | 0.200 |
Why?
|
| Sarcoidosis | 1 | 2008 | 537 | 0.200 |
Why?
|
| Autoimmune Lymphoproliferative Syndrome | 1 | 2022 | 13 | 0.200 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 2527 | 0.200 |
Why?
|
| Plasmids | 11 | 2012 | 2261 | 0.200 |
Why?
|
| Neovascularization, Physiologic | 2 | 2008 | 1347 | 0.200 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2013 | 2293 | 0.200 |
Why?
|
| Sulfonamides | 2 | 2011 | 1977 | 0.190 |
Why?
|
| Health Care Reform | 1 | 2011 | 1247 | 0.190 |
Why?
|
| Angiogenic Proteins | 2 | 2013 | 101 | 0.190 |
Why?
|
| Bone Marrow Cells | 2 | 2006 | 2410 | 0.190 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2003 | 411 | 0.190 |
Why?
|
| Cause of Death | 1 | 2012 | 3688 | 0.190 |
Why?
|
| Sciatic Nerve | 3 | 2000 | 618 | 0.190 |
Why?
|
| 3T3 Cells | 5 | 2015 | 1083 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 3 | 2016 | 1963 | 0.180 |
Why?
|
| Interferons | 2 | 2020 | 702 | 0.180 |
Why?
|
| Decanoic Acids | 1 | 2001 | 68 | 0.180 |
Why?
|
| Luciferases | 4 | 2013 | 710 | 0.180 |
Why?
|
| Laminectomy | 2 | 2018 | 225 | 0.180 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2021 | 84 | 0.180 |
Why?
|
| Genes, Reporter | 3 | 2020 | 1518 | 0.180 |
Why?
|
| Electric Stimulation Therapy | 1 | 2007 | 625 | 0.180 |
Why?
|
| Green Fluorescent Proteins | 6 | 2013 | 2062 | 0.180 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2020 | 937 | 0.180 |
Why?
|
| Hospital Charges | 1 | 2023 | 350 | 0.180 |
Why?
|
| Apoptosis | 14 | 2021 | 9477 | 0.180 |
Why?
|
| Dependovirus | 2 | 2022 | 712 | 0.180 |
Why?
|
| Gene Expression Profiling | 6 | 2021 | 9416 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2018 | 2803 | 0.180 |
Why?
|
| Up-Regulation | 6 | 2021 | 4111 | 0.180 |
Why?
|
| Patient Care Planning | 1 | 2006 | 901 | 0.180 |
Why?
|
| Thromboembolism | 1 | 2007 | 992 | 0.180 |
Why?
|
| DNA Methylation | 2 | 2018 | 4384 | 0.180 |
Why?
|
| Receptors, LDL | 1 | 2003 | 489 | 0.180 |
Why?
|
| Hypersensitivity | 1 | 2009 | 1167 | 0.180 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 3 | 1998 | 244 | 0.180 |
Why?
|
| Blotting, Western | 10 | 2016 | 5032 | 0.180 |
Why?
|
| Genes, Neurofibromatosis 2 | 2 | 2000 | 122 | 0.170 |
Why?
|
| Pyrazoles | 1 | 2010 | 2010 | 0.170 |
Why?
|
| Gene Order | 2 | 2018 | 168 | 0.170 |
Why?
|
| Aged | 26 | 2024 | 169288 | 0.170 |
Why?
|
| Gene Expression Regulation, Viral | 3 | 2013 | 433 | 0.170 |
Why?
|
| Lysosomes | 2 | 2015 | 921 | 0.170 |
Why?
|
| Antiviral Agents | 8 | 2016 | 3048 | 0.170 |
Why?
|
| Mesenchymal Stem Cells | 3 | 2016 | 1645 | 0.170 |
Why?
|
| Thoracic Neoplasms | 1 | 2002 | 268 | 0.160 |
Why?
|
| Nitriles | 1 | 2024 | 971 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 5300 | 0.160 |
Why?
|
| Adjuvants, Immunologic | 4 | 2022 | 988 | 0.160 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 3366 | 0.160 |
Why?
|
| Transplantation, Heterologous | 9 | 2017 | 2381 | 0.160 |
Why?
|
| Pyridones | 1 | 2024 | 809 | 0.160 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2018 | 1360 | 0.160 |
Why?
|
| Pericytes | 2 | 2019 | 294 | 0.160 |
Why?
|
| Vestibular Diseases | 1 | 2022 | 231 | 0.160 |
Why?
|
| Platinum | 1 | 2020 | 220 | 0.160 |
Why?
|
| Octamer Transcription Factor-1 | 2 | 2015 | 30 | 0.160 |
Why?
|
| beta-Galactosidase | 4 | 2004 | 574 | 0.160 |
Why?
|
| Nanostructures | 1 | 2024 | 551 | 0.160 |
Why?
|
| Reoperation | 2 | 2007 | 4303 | 0.160 |
Why?
|
| Adult | 36 | 2024 | 221119 | 0.160 |
Why?
|
| Middle Aged | 32 | 2024 | 220853 | 0.160 |
Why?
|
| Biological Transport | 3 | 2020 | 2080 | 0.150 |
Why?
|
| Neurotoxins | 1 | 1999 | 240 | 0.150 |
Why?
|
| Heart Diseases | 1 | 2011 | 2795 | 0.150 |
Why?
|
| Nucleoside Deaminases | 1 | 1998 | 58 | 0.150 |
Why?
|
| Stathmin | 1 | 2018 | 70 | 0.150 |
Why?
|
| Intensive Care Units | 1 | 2012 | 3744 | 0.150 |
Why?
|
| Genes, Viral | 1 | 1999 | 649 | 0.150 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3691 | 0.150 |
Why?
|
| Osmium | 1 | 2017 | 18 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2020 | 6486 | 0.150 |
Why?
|
| Antigen Presentation | 1 | 2023 | 1251 | 0.150 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2003 | 395 | 0.150 |
Why?
|
| Brain Mapping | 2 | 2015 | 6635 | 0.150 |
Why?
|
| Hematologic Diseases | 1 | 2022 | 496 | 0.150 |
Why?
|
| Hospital Mortality | 1 | 2012 | 5295 | 0.150 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2017 | 43 | 0.150 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2018 | 183 | 0.150 |
Why?
|
| Petrous Bone | 3 | 2012 | 85 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 793 | 0.140 |
Why?
|
| Syringomyelia | 1 | 2018 | 67 | 0.140 |
Why?
|
| Cell-Derived Microparticles | 1 | 2019 | 161 | 0.140 |
Why?
|
| Gene Expression Regulation | 10 | 2019 | 11856 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 1304 | 0.140 |
Why?
|
| Cytopathogenic Effect, Viral | 6 | 2012 | 151 | 0.140 |
Why?
|
| Antibodies, Blocking | 1 | 2017 | 249 | 0.140 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2020 | 504 | 0.140 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2015 | 1967 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2021 | 566 | 0.140 |
Why?
|
| Coordination Complexes | 1 | 2017 | 73 | 0.140 |
Why?
|
| Macrophages | 4 | 2007 | 5753 | 0.140 |
Why?
|
| Vinblastine | 1 | 2018 | 488 | 0.140 |
Why?
|
| Janus Kinase 2 | 1 | 2020 | 559 | 0.140 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2018 | 176 | 0.140 |
Why?
|
| Biotransformation | 3 | 2005 | 166 | 0.140 |
Why?
|
| Injections, Intralesional | 4 | 2004 | 280 | 0.140 |
Why?
|
| Research Support as Topic | 1 | 2021 | 697 | 0.140 |
Why?
|
| Decompression, Surgical | 2 | 2018 | 607 | 0.140 |
Why?
|
| Ischemia | 1 | 2005 | 1889 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 11 | 2020 | 22127 | 0.140 |
Why?
|
| Thioguanine | 1 | 1996 | 45 | 0.140 |
Why?
|
| Cognition | 1 | 2014 | 6988 | 0.130 |
Why?
|
| Drug Delivery Systems | 4 | 2023 | 2223 | 0.130 |
Why?
|
| Escherichia coli | 6 | 2001 | 4201 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 12 | 2017 | 6199 | 0.130 |
Why?
|
| Guidelines as Topic | 2 | 2017 | 1385 | 0.130 |
Why?
|
| Brain Edema | 1 | 2020 | 604 | 0.130 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 619 | 0.130 |
Why?
|
| Receptors, Transferrin | 4 | 2004 | 291 | 0.130 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2018 | 159 | 0.130 |
Why?
|
| Oligodendroglioma | 2 | 2010 | 278 | 0.130 |
Why?
|
| Epitopes | 2 | 2024 | 2504 | 0.130 |
Why?
|
| Vaccines, Attenuated | 1 | 2017 | 315 | 0.130 |
Why?
|
| Skin Neoplasms | 2 | 2015 | 5809 | 0.130 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2016 | 135 | 0.130 |
Why?
|
| Retinal Neoplasms | 1 | 1998 | 148 | 0.130 |
Why?
|
| Genome | 2 | 2003 | 1738 | 0.130 |
Why?
|
| Microtubule Proteins | 1 | 2015 | 62 | 0.130 |
Why?
|
| Cells, Cultured | 12 | 2020 | 18926 | 0.130 |
Why?
|
| Hydrocephalus, Normal Pressure | 1 | 2016 | 98 | 0.130 |
Why?
|
| Face | 1 | 2022 | 1025 | 0.130 |
Why?
|
| Neural Tube Defects | 1 | 2018 | 255 | 0.130 |
Why?
|
| NF-kappa B | 2 | 2021 | 2475 | 0.130 |
Why?
|
| Tyrosine | 1 | 2020 | 1422 | 0.130 |
Why?
|
| Immunosuppressive Agents | 5 | 2015 | 4190 | 0.120 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2020 | 790 | 0.120 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2017 | 282 | 0.120 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2010 | 1168 | 0.120 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2020 | 736 | 0.120 |
Why?
|
| Length of Stay | 3 | 2023 | 6417 | 0.120 |
Why?
|
| Inflammation | 4 | 2012 | 10759 | 0.120 |
Why?
|
| Neoplasm Seeding | 1 | 2015 | 84 | 0.120 |
Why?
|
| Retinoblastoma | 1 | 1998 | 319 | 0.120 |
Why?
|
| Leupeptins | 1 | 2014 | 112 | 0.120 |
Why?
|
| HEK293 Cells | 4 | 2020 | 4243 | 0.120 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2015 | 1111 | 0.120 |
Why?
|
| Antibodies, Viral | 3 | 2017 | 3149 | 0.120 |
Why?
|
| E2F1 Transcription Factor | 1 | 2015 | 178 | 0.120 |
Why?
|
| Luminescent Proteins | 5 | 2010 | 834 | 0.120 |
Why?
|
| Tight Junctions | 1 | 2017 | 324 | 0.120 |
Why?
|
| Acetyltransferases | 1 | 2015 | 231 | 0.120 |
Why?
|
| Steroid Hydroxylases | 1 | 1994 | 93 | 0.120 |
Why?
|
| 3' Untranslated Regions | 2 | 2014 | 514 | 0.120 |
Why?
|
| Abnormalities, Multiple | 1 | 2022 | 1423 | 0.120 |
Why?
|
| Caspase 3 | 1 | 2016 | 730 | 0.120 |
Why?
|
| Phenotype | 7 | 2021 | 16575 | 0.110 |
Why?
|
| Retinoids | 3 | 1989 | 99 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 5842 | 0.110 |
Why?
|
| Cerebrum | 1 | 2015 | 132 | 0.110 |
Why?
|
| Transcription, Genetic | 6 | 2015 | 7571 | 0.110 |
Why?
|
| Serotonin | 1 | 2018 | 1042 | 0.110 |
Why?
|
| Fluorescence | 3 | 2011 | 751 | 0.110 |
Why?
|
| Flow Cytometry | 6 | 2015 | 5871 | 0.110 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2016 | 394 | 0.110 |
Why?
|
| Protein Transport | 2 | 2017 | 1958 | 0.110 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2017 | 830 | 0.110 |
Why?
|
| Enzyme Inhibitors | 3 | 2016 | 3702 | 0.110 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2016 | 457 | 0.110 |
Why?
|
| Magnetics | 1 | 2016 | 598 | 0.110 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2014 | 127 | 0.110 |
Why?
|
| Melatonin | 1 | 2018 | 668 | 0.110 |
Why?
|
| Microtubules | 2 | 2016 | 1071 | 0.110 |
Why?
|
| Suppression, Genetic | 1 | 2013 | 190 | 0.110 |
Why?
|
| Capsid | 1 | 2015 | 433 | 0.110 |
Why?
|
| Cell Communication | 1 | 2020 | 1651 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 15841 | 0.100 |
Why?
|
| RNA, Small Interfering | 4 | 2015 | 3412 | 0.100 |
Why?
|
| Stem Cell Niche | 1 | 2016 | 345 | 0.100 |
Why?
|
| Acetylation | 1 | 2015 | 1050 | 0.100 |
Why?
|
| Neostriatum | 1 | 1994 | 247 | 0.100 |
Why?
|
| Morpholines | 1 | 2016 | 581 | 0.100 |
Why?
|
| Follow-Up Studies | 12 | 2020 | 39126 | 0.100 |
Why?
|
| Bradykinin | 5 | 1999 | 205 | 0.100 |
Why?
|
| Doxycycline | 1 | 2014 | 344 | 0.100 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2012 | 36 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2020 | 3512 | 0.100 |
Why?
|
| Molybdenum | 1 | 2012 | 45 | 0.100 |
Why?
|
| Neurofibromatosis 2 | 3 | 2005 | 383 | 0.100 |
Why?
|
| Tocotrienols | 1 | 2012 | 3 | 0.100 |
Why?
|
| Retrospective Studies | 15 | 2023 | 80674 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2022 | 2159 | 0.100 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2012 | 134 | 0.100 |
Why?
|
| Adenoviruses, Human | 1 | 1994 | 255 | 0.100 |
Why?
|
| Neurons | 9 | 2014 | 9428 | 0.100 |
Why?
|
| Forecasting | 4 | 2012 | 2928 | 0.100 |
Why?
|
| Neurilemmoma | 4 | 2005 | 523 | 0.100 |
Why?
|
| Aminopyridines | 1 | 2016 | 573 | 0.100 |
Why?
|
| Tubulin | 1 | 2015 | 692 | 0.100 |
Why?
|
| Neuroprotective Agents | 1 | 2018 | 956 | 0.100 |
Why?
|
| Lymphoma | 2 | 2005 | 1898 | 0.100 |
Why?
|
| Peptides, Cyclic | 2 | 2019 | 392 | 0.100 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 890 | 0.100 |
Why?
|
| Mice, Transgenic | 3 | 2012 | 9520 | 0.100 |
Why?
|
| Intermediate Filament Proteins | 3 | 2011 | 262 | 0.100 |
Why?
|
| Antigens, Ly | 1 | 2012 | 294 | 0.100 |
Why?
|
| Cytosol | 1 | 2014 | 883 | 0.090 |
Why?
|
| RNA Interference | 3 | 2015 | 2816 | 0.090 |
Why?
|
| Muscle Neoplasms | 1 | 2012 | 130 | 0.090 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2011 | 83 | 0.090 |
Why?
|
| Vesiculovirus | 1 | 2011 | 55 | 0.090 |
Why?
|
| Endocytosis | 1 | 2015 | 950 | 0.090 |
Why?
|
| Colonic Neoplasms | 5 | 2002 | 2527 | 0.090 |
Why?
|
| Chondroitin ABC Lyase | 1 | 2010 | 15 | 0.090 |
Why?
|
| Trans-Activators | 2 | 2007 | 2846 | 0.090 |
Why?
|
| Free Tissue Flaps | 1 | 2015 | 331 | 0.090 |
Why?
|
| Selection Bias | 2 | 2015 | 359 | 0.090 |
Why?
|
| Nerve Growth Factors | 1 | 1994 | 564 | 0.090 |
Why?
|
| Mice, Knockout | 6 | 2014 | 14392 | 0.090 |
Why?
|
| Time Factors | 15 | 2017 | 39957 | 0.090 |
Why?
|
| Microfluidics | 1 | 2016 | 651 | 0.090 |
Why?
|
| Salvage Therapy | 1 | 2017 | 1264 | 0.090 |
Why?
|
| Carcinoma | 5 | 2002 | 2330 | 0.090 |
Why?
|
| Chelating Agents | 1 | 2012 | 383 | 0.090 |
Why?
|
| Small Molecule Libraries | 1 | 2016 | 731 | 0.090 |
Why?
|
| Chondroitin Sulfates | 1 | 2010 | 174 | 0.090 |
Why?
|
| Postoperative Care | 2 | 2023 | 1468 | 0.090 |
Why?
|
| Virus Assembly | 2 | 2003 | 139 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2009 | 1057 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 1878 | 0.090 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2011 | 412 | 0.090 |
Why?
|
| Radioimmunotherapy | 1 | 2010 | 90 | 0.090 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2002 | 189 | 0.090 |
Why?
|
| Lymphocyte Activation | 2 | 2018 | 5478 | 0.090 |
Why?
|
| Adoptive Transfer | 1 | 2012 | 823 | 0.090 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2019 | 617 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2014 | 548 | 0.090 |
Why?
|
| Ganglia, Spinal | 1 | 2012 | 525 | 0.090 |
Why?
|
| Liver Diseases | 1 | 2018 | 1301 | 0.090 |
Why?
|
| Virion | 4 | 2006 | 422 | 0.080 |
Why?
|
| Research Design | 3 | 2021 | 6180 | 0.080 |
Why?
|
| Copper | 1 | 2012 | 365 | 0.080 |
Why?
|
| Anesthesia, Inhalation | 1 | 2010 | 221 | 0.080 |
Why?
|
| Interferon Type I | 1 | 2013 | 557 | 0.080 |
Why?
|
| Cell Cycle Proteins | 2 | 2007 | 3446 | 0.080 |
Why?
|
| Parkinson Disease | 1 | 2003 | 2867 | 0.080 |
Why?
|
| Stroke | 1 | 2011 | 9721 | 0.080 |
Why?
|
| Genome, Viral | 2 | 2003 | 665 | 0.080 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2012 | 531 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2009 | 190 | 0.080 |
Why?
|
| DNA | 7 | 2004 | 7189 | 0.080 |
Why?
|
| CpG Islands | 1 | 2013 | 1190 | 0.080 |
Why?
|
| Osteoporosis | 1 | 2018 | 1604 | 0.080 |
Why?
|
| Neck Muscles | 1 | 2009 | 100 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 326 | 0.080 |
Why?
|
| Preoperative Period | 1 | 2011 | 551 | 0.080 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2008 | 37 | 0.080 |
Why?
|
| Host-Pathogen Interactions | 1 | 2017 | 1448 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 11101 | 0.080 |
Why?
|
| Autoantigens | 1 | 2012 | 888 | 0.080 |
Why?
|
| Intraoperative Period | 1 | 2009 | 510 | 0.080 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2010 | 261 | 0.080 |
Why?
|
| Lithium Chloride | 1 | 2008 | 82 | 0.080 |
Why?
|
| Epidural Space | 1 | 2009 | 123 | 0.080 |
Why?
|
| Drug Approval | 1 | 2015 | 812 | 0.080 |
Why?
|
| Neuroglia | 4 | 2019 | 953 | 0.080 |
Why?
|
| Virus Activation | 2 | 2020 | 319 | 0.080 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 2009 | 115 | 0.070 |
Why?
|
| Terpenes | 2 | 1998 | 96 | 0.070 |
Why?
|
| Brain Diseases | 2 | 2013 | 1545 | 0.070 |
Why?
|
| Etoposide | 1 | 2009 | 635 | 0.070 |
Why?
|
| Cervical Atlas | 1 | 2007 | 22 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 3778 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 2827 | 0.070 |
Why?
|
| Glucose | 3 | 2015 | 4342 | 0.070 |
Why?
|
| End Stage Liver Disease | 1 | 2012 | 352 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 3777 | 0.070 |
Why?
|
| Ependymoma | 1 | 2010 | 320 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 2635 | 0.070 |
Why?
|
| Fibrous Dysplasia, Polyostotic | 1 | 2007 | 39 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2010 | 548 | 0.070 |
Why?
|
| Neuroimmunomodulation | 1 | 2009 | 184 | 0.070 |
Why?
|
| RNA, Viral | 1 | 2015 | 2839 | 0.070 |
Why?
|
| Membrane Proteins | 3 | 2022 | 7851 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 1662 | 0.070 |
Why?
|
| Vincristine | 1 | 2009 | 1036 | 0.070 |
Why?
|
| Receptor, Notch1 | 1 | 2009 | 497 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2015 | 2881 | 0.070 |
Why?
|
| Brain Injuries | 1 | 2018 | 2054 | 0.070 |
Why?
|
| Adaptive Immunity | 2 | 2022 | 724 | 0.070 |
Why?
|
| Necrosis | 4 | 2011 | 1610 | 0.070 |
Why?
|
| Proteomics | 3 | 2018 | 3840 | 0.070 |
Why?
|
| Nervous System Neoplasms | 1 | 2006 | 91 | 0.070 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2012 | 1116 | 0.070 |
Why?
|
| Mitotic Index | 1 | 2006 | 162 | 0.070 |
Why?
|
| Medical Oncology | 3 | 2021 | 2320 | 0.070 |
Why?
|
| Vertebroplasty | 1 | 2007 | 78 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 694 | 0.070 |
Why?
|
| Arm | 1 | 2009 | 589 | 0.070 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 2024 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2002 | 1838 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2005 | 34 | 0.060 |
Why?
|
| Age Factors | 4 | 2015 | 18384 | 0.060 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2009 | 260 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2012 | 1316 | 0.060 |
Why?
|
| Embolization, Therapeutic | 1 | 2015 | 1419 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 1995 | 1589 | 0.060 |
Why?
|
| Protons | 2 | 2021 | 1111 | 0.060 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2013 | 1249 | 0.060 |
Why?
|
| Vaccines | 1 | 2014 | 835 | 0.060 |
Why?
|
| Alcoholism | 1 | 2016 | 1973 | 0.060 |
Why?
|
| Optics and Photonics | 1 | 2007 | 305 | 0.060 |
Why?
|
| Models, Animal | 4 | 2006 | 2115 | 0.060 |
Why?
|
| Career Choice | 1 | 2012 | 757 | 0.060 |
Why?
|
| Bone Cements | 1 | 2007 | 325 | 0.060 |
Why?
|
| Blood Volume | 2 | 2004 | 547 | 0.060 |
Why?
|
| Tretinoin | 1 | 1988 | 517 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 4537 | 0.060 |
Why?
|
| RNA-Binding Proteins | 3 | 2020 | 1855 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 20119 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 1702 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2020 | 10756 | 0.060 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2004 | 14 | 0.060 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2006 | 282 | 0.060 |
Why?
|
| Cricetinae | 2 | 2012 | 2412 | 0.060 |
Why?
|
| Dogs | 4 | 2012 | 3832 | 0.060 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 931 | 0.060 |
Why?
|
| Gene Deletion | 5 | 2010 | 2658 | 0.060 |
Why?
|
| NIH 3T3 Cells | 2 | 2019 | 667 | 0.060 |
Why?
|
| Meninges | 1 | 2006 | 197 | 0.060 |
Why?
|
| Proteome | 1 | 2014 | 1856 | 0.060 |
Why?
|
| Phagocytes | 1 | 2006 | 294 | 0.060 |
Why?
|
| Recombination, Genetic | 3 | 2012 | 1518 | 0.060 |
Why?
|
| Prednisone | 1 | 2009 | 1565 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 1089 | 0.060 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 1664 | 0.060 |
Why?
|
| Angiography | 2 | 2009 | 1597 | 0.060 |
Why?
|
| Risk Factors | 6 | 2015 | 74239 | 0.060 |
Why?
|
| Chemokine CXCL12 | 1 | 2006 | 454 | 0.060 |
Why?
|
| Equipment Failure | 1 | 2007 | 580 | 0.060 |
Why?
|
| Base Sequence | 6 | 2020 | 12404 | 0.060 |
Why?
|
| Radiation Dosage | 2 | 2011 | 1962 | 0.060 |
Why?
|
| Cosmids | 2 | 2001 | 105 | 0.060 |
Why?
|
| NADPH-Ferrihemoprotein Reductase | 1 | 2004 | 30 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2015 | 2877 | 0.060 |
Why?
|
| Ki-67 Antigen | 1 | 2006 | 628 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2012 | 6223 | 0.060 |
Why?
|
| Radiography | 2 | 2012 | 6974 | 0.060 |
Why?
|
| Phosphorylation | 4 | 2018 | 8300 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 5666 | 0.060 |
Why?
|
| Neuroma, Acoustic | 4 | 2005 | 458 | 0.060 |
Why?
|
| Diagnostic Imaging | 2 | 2011 | 3534 | 0.060 |
Why?
|
| Young Adult | 8 | 2018 | 59221 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 2820 | 0.050 |
Why?
|
| Mammalian orthoreovirus 3 | 1 | 2003 | 45 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2007 | 9566 | 0.050 |
Why?
|
| Breast Neoplasms | 4 | 2024 | 20982 | 0.050 |
Why?
|
| Homeostasis | 1 | 2014 | 3320 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 1506 | 0.050 |
Why?
|
| Cell Differentiation | 4 | 2009 | 11509 | 0.050 |
Why?
|
| Cell Death | 3 | 2002 | 1676 | 0.050 |
Why?
|
| Receptors, Virus | 2 | 2020 | 642 | 0.050 |
Why?
|
| Callithrix | 1 | 2003 | 95 | 0.050 |
Why?
|
| Sterols | 1 | 2003 | 64 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2009 | 115 | 0.050 |
Why?
|
| Histocytochemistry | 2 | 1994 | 697 | 0.050 |
Why?
|
| Receptors, AMPA | 1 | 2024 | 335 | 0.050 |
Why?
|
| Random Allocation | 2 | 2023 | 2393 | 0.050 |
Why?
|
| Homozygote | 1 | 2008 | 1775 | 0.050 |
Why?
|
| STAT Transcription Factors | 1 | 2023 | 188 | 0.050 |
Why?
|
| Recombinant Proteins | 5 | 2008 | 6504 | 0.050 |
Why?
|
| Transformation, Genetic | 1 | 2003 | 192 | 0.050 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2003 | 65 | 0.050 |
Why?
|
| Blotting, Southern | 2 | 2001 | 775 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2009 | 1892 | 0.050 |
Why?
|
| Endothelial Cells | 3 | 2017 | 3551 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2019 | 5775 | 0.050 |
Why?
|
| Cytosine Deaminase | 2 | 2004 | 66 | 0.050 |
Why?
|
| Herpesviridae | 1 | 2003 | 104 | 0.050 |
Why?
|
| Sleep | 1 | 2018 | 4759 | 0.050 |
Why?
|
| Indoles | 3 | 2015 | 1830 | 0.050 |
Why?
|
| Janus Kinases | 1 | 2023 | 248 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2009 | 2224 | 0.050 |
Why?
|
| Endoscopy | 1 | 2012 | 1852 | 0.050 |
Why?
|
| Methotrexate | 1 | 2009 | 1718 | 0.050 |
Why?
|
| Kynurenine | 1 | 2023 | 141 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2010 | 1405 | 0.050 |
Why?
|
| Genetic Complementation Test | 1 | 2003 | 556 | 0.050 |
Why?
|
| Formaldehyde | 1 | 2024 | 357 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2008 | 1176 | 0.050 |
Why?
|
| HeLa Cells | 3 | 2017 | 3073 | 0.050 |
Why?
|
| Chemokine CCL5 | 1 | 2022 | 214 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 664 | 0.050 |
Why?
|
| Cerebellum | 1 | 2009 | 1501 | 0.050 |
Why?
|
| Survival Rate | 4 | 2005 | 12728 | 0.050 |
Why?
|
| Camptothecin | 1 | 2005 | 591 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2011 | 4909 | 0.050 |
Why?
|
| HT29 Cells | 3 | 2012 | 192 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2007 | 1525 | 0.050 |
Why?
|
| Ohio | 1 | 2022 | 322 | 0.050 |
Why?
|
| Cell Adhesion | 3 | 2016 | 3091 | 0.050 |
Why?
|
| Oxides | 3 | 2002 | 401 | 0.050 |
Why?
|
| Arabinofuranosyluracil | 1 | 2001 | 10 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 4 | 2011 | 4404 | 0.050 |
Why?
|
| Oximes | 1 | 2023 | 303 | 0.050 |
Why?
|
| Carcinogens | 1 | 2004 | 452 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2006 | 1129 | 0.050 |
Why?
|
| Neurofibromin 2 | 2 | 2000 | 269 | 0.050 |
Why?
|
| Phosphoramide Mustards | 1 | 2001 | 18 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2006 | 2621 | 0.050 |
Why?
|
| Macaca | 1 | 2022 | 410 | 0.050 |
Why?
|
| Spinal Cord | 1 | 2009 | 1807 | 0.050 |
Why?
|
| Interleukins | 1 | 2006 | 782 | 0.050 |
Why?
|
| Coculture Techniques | 2 | 2017 | 1334 | 0.050 |
Why?
|
| Rodentia | 1 | 2022 | 261 | 0.050 |
Why?
|
| Cervical Vertebrae | 1 | 2007 | 976 | 0.050 |
Why?
|
| Stem Cell Transplantation | 2 | 2007 | 1600 | 0.050 |
Why?
|
| Tryptophan | 1 | 2023 | 480 | 0.050 |
Why?
|
| Models, Structural | 1 | 2001 | 338 | 0.050 |
Why?
|
| Consensus | 2 | 2021 | 3134 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2008 | 2916 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2003 | 2171 | 0.050 |
Why?
|
| Aged, 80 and over | 8 | 2017 | 58952 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2007 | 2643 | 0.040 |
Why?
|
| Spinal Fractures | 1 | 2007 | 704 | 0.040 |
Why?
|
| Elapid Venoms | 1 | 2000 | 40 | 0.040 |
Why?
|
| Radial Nerve | 1 | 2000 | 42 | 0.040 |
Why?
|
| Nanofibers | 2 | 2011 | 66 | 0.040 |
Why?
|
| Societies | 1 | 2021 | 107 | 0.040 |
Why?
|
| Tyrosine Transaminase | 1 | 2020 | 11 | 0.040 |
Why?
|
| Dominance, Cerebral | 3 | 2004 | 623 | 0.040 |
Why?
|
| Arteries | 1 | 2005 | 1121 | 0.040 |
Why?
|
| CHO Cells | 1 | 2003 | 1379 | 0.040 |
Why?
|
| Cell Growth Processes | 2 | 2015 | 382 | 0.040 |
Why?
|
| Injections, Intraventricular | 3 | 2014 | 225 | 0.040 |
Why?
|
| Adaptation, Biological | 1 | 2001 | 147 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5321 | 0.040 |
Why?
|
| Complement Activation | 1 | 2002 | 445 | 0.040 |
Why?
|
| Primates | 1 | 2022 | 521 | 0.040 |
Why?
|
| Adolescent | 9 | 2022 | 88298 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 2011 | 2642 | 0.040 |
Why?
|
| Disease Progression | 6 | 2017 | 13511 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2012 | 2374 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2005 | 1111 | 0.040 |
Why?
|
| Tissue Engineering | 1 | 2009 | 1865 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2023 | 41496 | 0.040 |
Why?
|
| Injections | 2 | 2000 | 832 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 2455 | 0.040 |
Why?
|
| Endothelium, Vascular | 3 | 2005 | 4420 | 0.040 |
Why?
|
| Risk | 1 | 2011 | 9616 | 0.040 |
Why?
|
| Viral Vaccines | 1 | 2004 | 593 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 329 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2023 | 475 | 0.040 |
Why?
|
| Receptors, Melatonin | 1 | 2018 | 31 | 0.040 |
Why?
|
| COS Cells | 2 | 2011 | 1129 | 0.040 |
Why?
|
| Carbon Dioxide | 1 | 2003 | 1147 | 0.040 |
Why?
|
| Receptor, Melatonin, MT1 | 1 | 2018 | 31 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2015 | 1331 | 0.040 |
Why?
|
| Laughter | 1 | 1998 | 19 | 0.040 |
Why?
|
| Propensity Score | 2 | 2017 | 1916 | 0.040 |
Why?
|
| Nitrogen | 1 | 2020 | 345 | 0.040 |
Why?
|
| Drug Resistance | 2 | 1994 | 1594 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2020 | 13402 | 0.040 |
Why?
|
| Anthracenes | 1 | 1998 | 83 | 0.040 |
Why?
|
| Preoperative Care | 2 | 2019 | 2241 | 0.040 |
Why?
|
| Anesthesia | 1 | 2009 | 1591 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2019 | 1432 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2006 | 2208 | 0.040 |
Why?
|
| Galactosides | 1 | 1998 | 54 | 0.040 |
Why?
|
| Antimetabolites | 1 | 1998 | 129 | 0.040 |
Why?
|
| DNA Modification Methylases | 1 | 2018 | 210 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2009 | 3596 | 0.040 |
Why?
|
| Receptor, Melatonin, MT2 | 1 | 2018 | 82 | 0.040 |
Why?
|
| Culture Media, Conditioned | 2 | 1998 | 522 | 0.040 |
Why?
|
| Single-Chain Antibodies | 1 | 2018 | 111 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2002 | 1963 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2022 | 822 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2020 | 782 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2008 | 3210 | 0.040 |
Why?
|
| Genome, Human | 2 | 2020 | 4423 | 0.040 |
Why?
|
| Receptor Aggregation | 1 | 2017 | 72 | 0.040 |
Why?
|
| Ifosfamide | 1 | 1998 | 232 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2001 | 1681 | 0.040 |
Why?
|
| Cell-Penetrating Peptides | 1 | 2017 | 43 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2008 | 2974 | 0.040 |
Why?
|
| Species Specificity | 1 | 2002 | 2406 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2021 | 585 | 0.040 |
Why?
|
| Gamma Rays | 1 | 2019 | 318 | 0.040 |
Why?
|
| Chromosomes, Bacterial | 1 | 1998 | 280 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2019 | 252 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 2017 | 6067 | 0.040 |
Why?
|
| Critical Care | 1 | 2010 | 2696 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 899 | 0.040 |
Why?
|
| Antibody Formation | 2 | 1999 | 1391 | 0.040 |
Why?
|
| Thoracic Vertebrae | 1 | 2002 | 612 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2012 | 8998 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 2509 | 0.030 |
Why?
|
| Universities | 1 | 2022 | 995 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2020 | 428 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2018 | 346 | 0.030 |
Why?
|
| DNA, Neoplasm | 3 | 1998 | 1743 | 0.030 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2003 | 614 | 0.030 |
Why?
|
| Neurofibromatosis 1 | 2 | 1992 | 561 | 0.030 |
Why?
|
| Genes, p53 | 1 | 1999 | 713 | 0.030 |
Why?
|
| Spinal Cord Compression | 2 | 2009 | 234 | 0.030 |
Why?
|
| Drug Carriers | 1 | 2001 | 705 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 14675 | 0.030 |
Why?
|
| Receptors, Antigen | 1 | 2016 | 51 | 0.030 |
Why?
|
| Cisterna Magna | 1 | 1996 | 39 | 0.030 |
Why?
|
| Nanomedicine | 1 | 2019 | 289 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2008 | 4513 | 0.030 |
Why?
|
| Comorbidity | 1 | 2011 | 10516 | 0.030 |
Why?
|
| Models, Genetic | 2 | 2001 | 3430 | 0.030 |
Why?
|
| Histone Demethylases | 1 | 2019 | 322 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2020 | 1417 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2020 | 1226 | 0.030 |
Why?
|
| Osmosis | 1 | 1995 | 103 | 0.030 |
Why?
|
| Lymphokines | 1 | 2019 | 925 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2003 | 1333 | 0.030 |
Why?
|
| Fluphenazine | 1 | 2015 | 35 | 0.030 |
Why?
|
| Subrenal Capsule Assay | 2 | 1992 | 27 | 0.030 |
Why?
|
| Parietal Bone | 1 | 2015 | 49 | 0.030 |
Why?
|
| Mentors | 1 | 2021 | 663 | 0.030 |
Why?
|
| Moloney murine leukemia virus | 1 | 1995 | 109 | 0.030 |
Why?
|
| Protein Stability | 1 | 2017 | 579 | 0.030 |
Why?
|
| Frontal Sinus | 1 | 2015 | 51 | 0.030 |
Why?
|
| Virulence | 1 | 1999 | 1296 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 12676 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2006 | 3493 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2329 | 0.030 |
Why?
|
| Frontal Bone | 1 | 2015 | 105 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 1624 | 0.030 |
Why?
|
| Hospitalization | 1 | 2015 | 10707 | 0.030 |
Why?
|
| Permeability | 1 | 2017 | 721 | 0.030 |
Why?
|
| Microscopy | 2 | 2012 | 904 | 0.030 |
Why?
|
| Vimentin | 1 | 2016 | 255 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 14610 | 0.030 |
Why?
|
| Cerebral Aqueduct | 1 | 1994 | 40 | 0.030 |
Why?
|
| Iron | 3 | 2002 | 1790 | 0.030 |
Why?
|
| Academies and Institutes | 1 | 2017 | 318 | 0.030 |
Why?
|
| Diagnosis, Differential | 4 | 2005 | 12976 | 0.030 |
Why?
|
| Injections, Intra-Arterial | 3 | 1999 | 181 | 0.030 |
Why?
|
| Central Nervous System Diseases | 1 | 1999 | 521 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1999 | 1527 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2015 | 405 | 0.030 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2015 | 297 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 2017 | 558 | 0.030 |
Why?
|
| Acetylcholinesterase | 1 | 1994 | 156 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 5782 | 0.030 |
Why?
|
| Pregnancy | 2 | 2013 | 29893 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 2 | 2010 | 1067 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2016 | 656 | 0.030 |
Why?
|
| Tissue Distribution | 2 | 2012 | 2263 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2015 | 473 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2017 | 1900 | 0.030 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2015 | 242 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 2740 | 0.030 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2018 | 432 | 0.030 |
Why?
|
| Kinetics | 1 | 2001 | 6312 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2004 | 2888 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2020 | 3603 | 0.030 |
Why?
|
| Microspheres | 1 | 2016 | 783 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2000 | 1372 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 15308 | 0.030 |
Why?
|
| Fluorouracil | 1 | 1998 | 1642 | 0.030 |
Why?
|
| Sirolimus | 1 | 2020 | 1540 | 0.030 |
Why?
|
| Epigenesis, Genetic | 2 | 2019 | 3788 | 0.030 |
Why?
|
| Ligands | 2 | 2016 | 3264 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 1803 | 0.030 |
Why?
|
| Annexin A2 | 1 | 2012 | 43 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2007 | 20588 | 0.030 |
Why?
|
| Mitosis | 1 | 1998 | 1186 | 0.030 |
Why?
|
| Clinical Protocols | 2 | 2009 | 1436 | 0.030 |
Why?
|
| Plasmacytoma | 1 | 1993 | 171 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-2 | 2 | 2005 | 177 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 734 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 2001 | 1683 | 0.030 |
Why?
|
| Proto-Oncogene Protein c-ets-2 | 1 | 2011 | 15 | 0.030 |
Why?
|
| Tocopherols | 1 | 2012 | 44 | 0.020 |
Why?
|
| Neurofibroma | 1 | 1992 | 95 | 0.020 |
Why?
|
| Decision Making | 1 | 2006 | 3931 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 1995 | 959 | 0.020 |
Why?
|
| Cell Migration Assays | 1 | 2011 | 22 | 0.020 |
Why?
|
| Cyclic S-Oxides | 1 | 2011 | 25 | 0.020 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 3696 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2022 | 2756 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 4340 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2019 | 2706 | 0.020 |
Why?
|
| United States | 2 | 2021 | 72339 | 0.020 |
Why?
|
| Endoscopes | 1 | 2012 | 169 | 0.020 |
Why?
|
| Anthraquinones | 1 | 2011 | 41 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2012 | 5885 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 2012 | 323 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2017 | 1892 | 0.020 |
Why?
|
| Genes, erbB-1 | 2 | 2002 | 162 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2011 | 24021 | 0.020 |
Why?
|
| Myosin Type II | 1 | 2011 | 70 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 2802 | 0.020 |
Why?
|
| Cisplatin | 1 | 2017 | 1652 | 0.020 |
Why?
|
| Enzyme Induction | 2 | 1989 | 452 | 0.020 |
Why?
|
| Cloning, Molecular | 3 | 1998 | 4167 | 0.020 |
Why?
|
| Polystyrenes | 1 | 2011 | 104 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2024 | 8642 | 0.020 |
Why?
|
| Microcirculation | 2 | 2007 | 1280 | 0.020 |
Why?
|
| Methylation | 1 | 2013 | 1070 | 0.020 |
Why?
|
| Metabolomics | 1 | 2020 | 1658 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2016 | 931 | 0.020 |
Why?
|
| Eosinophilia | 1 | 1995 | 557 | 0.020 |
Why?
|
| Tomography | 1 | 2012 | 411 | 0.020 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 1990 | 152 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 1728 | 0.020 |
Why?
|
| Computers | 1 | 2012 | 591 | 0.020 |
Why?
|
| Cholangiocarcinoma | 1 | 2015 | 554 | 0.020 |
Why?
|
| Bile Duct Neoplasms | 1 | 2015 | 607 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 3634 | 0.020 |
Why?
|
| Prospective Studies | 4 | 2022 | 54435 | 0.020 |
Why?
|
| Equipment Design | 1 | 2018 | 3510 | 0.020 |
Why?
|
| Arrestins | 1 | 2009 | 73 | 0.020 |
Why?
|
| Regeneration | 1 | 2018 | 1505 | 0.020 |
Why?
|
| Venous Pressure | 1 | 2009 | 55 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2451 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2022 | 42224 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 12052 | 0.020 |
Why?
|
| Hybridomas | 1 | 1990 | 443 | 0.020 |
Why?
|
| Astrocytes | 1 | 2017 | 1340 | 0.020 |
Why?
|
| Neuroendocrine Tumors | 1 | 2015 | 642 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1602 | 0.020 |
Why?
|
| Retinol-Binding Proteins | 1 | 1989 | 67 | 0.020 |
Why?
|
| Densitometry | 1 | 1989 | 151 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 4739 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2011 | 506 | 0.020 |
Why?
|
| Molecular Probes | 2 | 2002 | 309 | 0.020 |
Why?
|
| Microfilament Proteins | 2 | 2007 | 1130 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 318 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 17897 | 0.020 |
Why?
|
| Cadaver | 1 | 2012 | 1358 | 0.020 |
Why?
|
| Histone Deacetylase 1 | 1 | 2009 | 133 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 1662 | 0.020 |
Why?
|
| DNA Fragmentation | 2 | 1998 | 237 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 17598 | 0.020 |
Why?
|
| Butyrates | 1 | 2008 | 169 | 0.020 |
Why?
|
| Biopsy | 3 | 2007 | 6781 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2010 | 803 | 0.020 |
Why?
|
| Vitamin E | 1 | 2012 | 872 | 0.020 |
Why?
|
| Patient Care Team | 1 | 1999 | 2515 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2018 | 3114 | 0.020 |
Why?
|
| Brain Stem | 1 | 2012 | 858 | 0.020 |
Why?
|
| Polyamines | 1 | 1988 | 133 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1989 | 1545 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2016 | 2548 | 0.020 |
Why?
|
| Liver | 4 | 2007 | 7514 | 0.020 |
Why?
|
| Child | 5 | 2022 | 80152 | 0.020 |
Why?
|
| Phosphonoacetic Acid | 1 | 2006 | 54 | 0.020 |
Why?
|
| Herpesviridae Infections | 1 | 2008 | 269 | 0.020 |
Why?
|
| Photons | 1 | 2010 | 589 | 0.020 |
Why?
|
| Infant | 2 | 2022 | 36169 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 1603 | 0.020 |
Why?
|
| Clone Cells | 2 | 2001 | 1668 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 2864 | 0.020 |
Why?
|
| Chemokine CCL21 | 1 | 2006 | 49 | 0.020 |
Why?
|
| Computational Biology | 1 | 2018 | 3499 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 2007 | 223 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 1186 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2009 | 598 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2009 | 848 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2011 | 1329 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2007 | 198 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2008 | 793 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2021 | 7966 | 0.020 |
Why?
|
| Neck Pain | 1 | 2007 | 190 | 0.020 |
Why?
|
| Quadriplegia | 1 | 2007 | 226 | 0.020 |
Why?
|
| Ferrosoferric Oxide | 2 | 1998 | 348 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 4052 | 0.020 |
Why?
|
| Injections, Spinal | 2 | 1996 | 317 | 0.020 |
Why?
|
| Radiculopathy | 1 | 2007 | 201 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2009 | 1462 | 0.020 |
Why?
|
| Chemokines, CC | 1 | 2006 | 283 | 0.020 |
Why?
|
| Protein Binding | 1 | 2017 | 9297 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 1141 | 0.020 |
Why?
|
| Genotype | 2 | 2015 | 12985 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 6819 | 0.010 |
Why?
|
| Tissue Scaffolds | 1 | 2011 | 932 | 0.010 |
Why?
|
| Hedgehog Proteins | 1 | 2009 | 769 | 0.010 |
Why?
|
| Monophenol Monooxygenase | 1 | 2004 | 72 | 0.010 |
Why?
|
| Genetic Markers | 2 | 2002 | 2599 | 0.010 |
Why?
|
| Albumins | 1 | 2007 | 575 | 0.010 |
Why?
|
| CD40 Ligand | 1 | 2006 | 524 | 0.010 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2010 | 801 | 0.010 |
Why?
|
| Restriction Mapping | 2 | 1998 | 849 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2008 | 1756 | 0.010 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2004 | 34 | 0.010 |
Why?
|
| Capillary Permeability | 1 | 2007 | 773 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2010 | 3577 | 0.010 |
Why?
|
| Electromyography | 1 | 2009 | 1393 | 0.010 |
Why?
|
| Adenovirus E1 Proteins | 1 | 2003 | 6 | 0.010 |
Why?
|
| Actins | 1 | 2011 | 2046 | 0.010 |
Why?
|
| Hand | 1 | 2009 | 902 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 2897 | 0.010 |
Why?
|
| Mucins | 1 | 2007 | 569 | 0.010 |
Why?
|
| Feasibility Studies | 3 | 2000 | 5250 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 5662 | 0.010 |
Why?
|
| Gyrus Cinguli | 1 | 1990 | 1114 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2005 | 459 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 10218 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2007 | 2468 | 0.010 |
Why?
|
| Safety | 1 | 2008 | 1151 | 0.010 |
Why?
|
| Cell Count | 1 | 2007 | 1831 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2010 | 1607 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 2010 | 1301 | 0.010 |
Why?
|
| Heparin | 1 | 1990 | 1632 | 0.010 |
Why?
|
| Algorithms | 4 | 2007 | 14025 | 0.010 |
Why?
|
| Purines | 1 | 2006 | 609 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 12474 | 0.010 |
Why?
|
| alpha-Synuclein | 1 | 2009 | 742 | 0.010 |
Why?
|
| Cell Separation | 1 | 2008 | 1721 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1990 | 1818 | 0.010 |
Why?
|
| Chromosomes, Artificial, P1 Bacteriophage | 1 | 2001 | 3 | 0.010 |
Why?
|
| Atrophy | 1 | 2007 | 1633 | 0.010 |
Why?
|
| Diuretics, Osmotic | 1 | 2002 | 33 | 0.010 |
Why?
|
| Mucin-1 | 1 | 2007 | 538 | 0.010 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2004 | 415 | 0.010 |
Why?
|
| Corpus Striatum | 1 | 2008 | 1234 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 2 | 2015 | 5366 | 0.010 |
Why?
|
| Drug Therapy, Combination | 2 | 2008 | 6304 | 0.010 |
Why?
|
| Telomerase | 1 | 2007 | 741 | 0.010 |
Why?
|
| Rare Diseases | 1 | 2007 | 624 | 0.010 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2004 | 485 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2002 | 221 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2005 | 1644 | 0.010 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2007 | 1075 | 0.010 |
Why?
|
| Mannitol | 1 | 2002 | 177 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2019 | 22174 | 0.010 |
Why?
|
| Colorectal Neoplasms | 2 | 1999 | 6919 | 0.010 |
Why?
|
| Choline | 1 | 2002 | 515 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2013 | 5103 | 0.010 |
Why?
|
| Tetrazolium Salts | 1 | 2000 | 92 | 0.010 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 1990 | 1492 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 3803 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2004 | 1498 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2002 | 328 | 0.010 |
Why?
|
| Autoradiography | 1 | 2001 | 729 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 2012 | 2332 | 0.010 |
Why?
|
| Leukocytes | 1 | 2007 | 2025 | 0.010 |
Why?
|
| Echo-Planar Imaging | 1 | 2004 | 663 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 1703 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 2000 | 252 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2003 | 1375 | 0.010 |
Why?
|
| Genes, Insect | 1 | 2000 | 265 | 0.010 |
Why?
|
| Schwann Cells | 1 | 2000 | 196 | 0.010 |
Why?
|
| Chromogenic Compounds | 1 | 1999 | 30 | 0.010 |
Why?
|
| Brain Abscess | 1 | 2000 | 120 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2000 | 346 | 0.010 |
Why?
|
| Insect Proteins | 1 | 2000 | 254 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2012 | 3410 | 0.010 |
Why?
|
| Membrane Transport Proteins | 1 | 2004 | 1031 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2003 | 2477 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 5493 | 0.010 |
Why?
|
| tau Proteins | 1 | 2009 | 2094 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1999 | 864 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 2928 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 8164 | 0.010 |
Why?
|
| Hamartoma | 1 | 2000 | 236 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2001 | 1123 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 1998 | 201 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2000 | 1429 | 0.010 |
Why?
|
| Massachusetts | 1 | 2010 | 8837 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 1998 | 216 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 2359 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 2001 | 1030 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2007 | 2465 | 0.010 |
Why?
|
| Genomics | 2 | 2004 | 5828 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2000 | 1751 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2000 | 838 | 0.010 |
Why?
|
| Incidence | 1 | 2015 | 21365 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 2691 | 0.010 |
Why?
|
| Mosaicism | 1 | 2000 | 477 | 0.010 |
Why?
|
| Occipital Bone | 1 | 1996 | 55 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 1791 | 0.010 |
Why?
|
| Cerebellopontine Angle | 1 | 1996 | 53 | 0.010 |
Why?
|
| Subarachnoid Space | 1 | 1996 | 80 | 0.010 |
Why?
|
| ROC Curve | 1 | 2004 | 3584 | 0.010 |
Why?
|
| Genes, Synthetic | 1 | 1996 | 88 | 0.010 |
Why?
|
| Glutathione | 1 | 1998 | 581 | 0.010 |
Why?
|
| Chromatin | 1 | 2007 | 2946 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2000 | 1695 | 0.010 |
Why?
|
| Liposomes | 1 | 1999 | 783 | 0.010 |
Why?
|
| Goals | 1 | 2000 | 710 | 0.010 |
Why?
|
| Cats | 1 | 1995 | 974 | 0.010 |
Why?
|
| Remission Induction | 1 | 2000 | 2392 | 0.010 |
Why?
|
| Cataract | 1 | 2000 | 828 | 0.010 |
Why?
|
| Retinal Diseases | 1 | 2000 | 705 | 0.010 |
Why?
|
| Immunization | 1 | 1998 | 1218 | 0.010 |
Why?
|
| Spinal Neoplasms | 1 | 2000 | 703 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2013 | 12099 | 0.010 |
Why?
|
| Age of Onset | 1 | 2000 | 3307 | 0.010 |
Why?
|
| Thiazoles | 1 | 2000 | 1517 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2007 | 5081 | 0.010 |
Why?
|
| Health Status | 1 | 2005 | 4077 | 0.010 |
Why?
|
| Carrier Proteins | 2 | 2000 | 4935 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2000 | 2603 | 0.010 |
Why?
|
| Temporal Bone | 1 | 1996 | 683 | 0.010 |
Why?
|
| Rabbits | 1 | 1998 | 4750 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1993 | 672 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2000 | 4107 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 1995 | 941 | 0.010 |
Why?
|
| Drosophila melanogaster | 1 | 2000 | 1710 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1991 | 259 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 11119 | 0.010 |
Why?
|
| Spleen | 1 | 1996 | 2290 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1991 | 1053 | 0.010 |
Why?
|
| DNA Damage | 1 | 1998 | 2442 | 0.000 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2000 | 2019 | 0.000 |
Why?
|
| Kidney | 1 | 2003 | 7033 | 0.000 |
Why?
|
| Receptors, Retinoic Acid | 1 | 1988 | 224 | 0.000 |
Why?
|
| Vaccination | 1 | 2000 | 3369 | 0.000 |
Why?
|
| Hippocampus | 1 | 1998 | 3754 | 0.000 |
Why?
|
| Epidermis | 1 | 1988 | 526 | 0.000 |
Why?
|
| Protein Biosynthesis | 1 | 1991 | 2091 | 0.000 |
Why?
|
| Binding Sites | 1 | 1991 | 5988 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1991 | 2413 | 0.000 |
Why?
|
| Monocytes | 1 | 1988 | 2570 | 0.000 |
Why?
|
| Proteins | 1 | 1988 | 5993 | 0.000 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1988 | 3609 | 0.000 |
Why?
|